- Home
- ECO vs LENZ Comparison
ECO vs LENZ Comparison
Compare ECO & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | LENZ |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 551.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECO | LENZ |
|---|---|---|
| Price | $32.75 | $17.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $37.00 | ★ $56.25 |
| AVG Volume (30 Days) | 254.0K | ★ 1.2M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | ★ 6.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $349,886,578.00 | $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.10 | $204.27 |
| P/E Ratio | $15.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.91 | $15.70 |
| 52 Week High | $39.77 | $50.40 |
Technical Indicators
Market Signals| Indicator | ECO | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 29.48 |
| Support Level | $31.82 | $16.26 |
| Resistance Level | $34.06 | $18.47 |
| Average True Range (ATR) | 0.83 | 2.06 |
| MACD | -0.51 | -0.40 |
| Stochastic Oscillator | 14.65 | 13.14 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.